AGT-181

DRUG3 trials

Sponsors

ArmaGen, Inc

Conditions

Mucopolysaccharidosis I

Phase 1

Extension Study of AGT-181-102 to Evaluate Long Term Safety and Activity of AGT-181

CompletedNCT02597114

ArmaGen, IncMucopolysaccharidosis I

Start: 2015-11-30End: 2018-08-02Updated: 2018-09-25

Safety and Dose Ranging Study of Human Insulin Receptor MAb-IDUA Fusion Protein in Adults and Children With MPS I

CompletedNCT03053089

ArmaGen, IncMucopolysaccharidosis I

Start: 2015-10-31End: 2018-02-01Updated: 2023-03-15

Extension Study Evaluating Long Term Safety and Activity of AGT-181 in Children With MPS I

CompletedNCT03071341

ArmaGen, IncMucopolysaccharidosis I

Start: 2016-10-31End: 2018-02-01Updated: 2023-03-15

Related Papers

Neurocognitive and somatic stabilization in pediatric patients with severe Mucopolysaccharidosis Type I after 52 weeks of intravenous brain-penetrating insulin receptor antibody-iduronidase fusion protein (valanafusp alpha): an open label phase 1-2 trial.

2018-07-05103 citations